No Data
Hainan Huluwa Pharmaceutical Group (605199.SH): Omeprazole enteric-coated capsules have passed the consistency evaluation for generic drugs.
Gelonghui reported on January 22 that Hainan Huluwa Pharmaceutical Group (605199.SH) announced the recent receipt of the approval notification for the supplementary application of Omeprazole enteric-coated capsules issued by the National Medical Products Administration. This pharmaceutical has passed the consistency evaluation of generic drug quality and efficacy. Omeprazole enteric-coated capsules are included in the national essential drugs list, the national medical insurance catalog, and provincial medical insurance catalogs, and are suitable for the treatment of gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome (gastrinoma).
Hainan Huluwa Pharmaceutical Group Asthma Drug Gets NMPA's Nod
Hainan Huluwa Pharmaceutical Group (605199.SH): Received the pharmaceutical registration certificate for inhalation solution of salbutamol sulfate.
On January 8, Gelonghui announced that Hainan Huluwa Pharmaceutical Group (605199.SH) has recently received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for inhaled salbutamol sulfate solution. The inhaled salbutamol sulfate solution is suitable for the treatment of chronic bronchospasm that is ineffective with traditional treatment methods and for the treatment of severe acute asthma attacks.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Hainan Huluwa Pharmaceutical Unit Passes GMP Compliance Inspection
Hainan Huluwa Pharmaceutical Group (605199.SH): The wholly-owned subsidiary received the Pharmaceutical GMP compliance inspection results.
Gelonghui December 31丨Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. (hereinafter referred to as "Guangxi Weiwei") recently received the "Notification of Pharmaceutical GMP Compliance Inspection Results" issued by the Guangxi Zhuang Autonomous Region Pharmaceutical Supervision and Administration Bureau. The company has acquired the pediatric phlegm-reducing cough granules from Guangxi Wuzhou Sanjian Pharmaceutical Co., Ltd. (Announcement No.: 2023-004) and has passed the GMP compliance inspection after completing the holder change.
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
